TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000SD4MAC7

Market Closed - Boerse Frankfurt Warrants 20:44:01 04/06/2024 BST
0.92 EUR +50.82% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL
Current month+61.54%
1 month-34.38%
Date Price Change
04/06/24 0.84 +37.70%
03/06/24 0.61 +17.31%
31/05/24 0.52 +15.56%
30/05/24 0.45 -16.67%
29/05/24 0.54 +14.89%

Real-time Boerse Frankfurt Warrants

Last update June 04, 2024 at 08:44 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SD4MAC
ISINDE000SD4MAC7
Date issued 12/03/2021
Strike 70.49 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.07
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.28
Lowest since issue 0.39

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
79.09 USD
Average target price
109.3 USD
Spread / Average Target
+38.23%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW